Federal Register of Legislation - Australian Government

Primary content

PB 53 of 2011 Arrangements as made
This instrument amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010) to make changes to the special arrangement relating to the highly specialised drugs program for hospitals.
Administered by: Health
Registered 27 Jul 2011
Tabling HistoryDate
Tabled HR18-Aug-2011
Tabled Senate18-Aug-2011
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

PB 53 of 2011

National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2011 (No. 7)

 

National Health Act 1953

___________________________________________________________________________

 

 

I, FELICITY MCNEILL, Acting First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Amendment Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.

Dated  22  July 2011

 

 

 

 

 

 

 

 

 

 

 

FELICITY MCNEILL

Acting First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

 

___________________________________________________________________________

 

 

 

 


1              Name of Instrument

 

(1)                This Instrument is the National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2011 (No.7).

 

(2)                This Instrument may also be cited as PB 53 of 2011.

 

2             Commencement

                             This Instrument commences on 1 August 2011.

3              Amendments to PB 116 of 2010

                Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010).

.

 

 


Schedule 1                   Amendments

 

[1]       Schedule 1, after entry for Epoetin Alfa in the form Injection 20,000 units in 0.5 mL pre-filled syringe

 

omit:

 

Injection 30,000 units in 0.75 mL pre‑filled syringe

Injection

Eprex 30,000

JC

EMP

C1957 C3334

 

12

5

D

 

 

[2]         Schedule 1, entry for Etanercept

 

omit from the column headed Responsible Person (all instances):

                    WX

 

             and substitute (all instances):

                    PF

 

[3]           Schedule 1, entry for Filgrastim

substitute:

 Filgrastim

Injection 120 micrograms in 0.2 mL single use pre-filled  syringe

Injection

Nivestim

HH

EMP

C2912 C2913

C2914 C2915

C2916 C2917

C2918 C2919

C2920 C2921

C2922 C2923

C2924 C2925

C2926 C2927

C2928 C2929

C2930 C3087

 

20

11

D

 

 

 

 

 

 

 

C3187 C3357

C3358 C3359

C3360 C3361

C3362 C3363

C3364 C3365

C3366 C3367

C3368 C3369

C3370 C3371

C3372 C3373

C3374 C3375

C3376 C3377

 

 

 

 

 

Injection 300 micrograms in 1 mL

Injection

Neupogen

AN

EMP

C2912 C2913

C2914 C2915

C2916 C2917

C2918 C2919

C2920 C2921

C2922 C2923

C2924 C2925

C2926 C2927

C2928 C2929

C2930 C3087

C3187 C3357

C3358 C3359

C3360 C3361

C3362 C3363

C3364 C3365

C3366 C3367

C3368 C3369

C3370 C3371

C3372 C3373

C3374 C3375

C3376 C3377

 

20

11

D

 

 

 

 

 

 

Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Neupogen)

Injection

Neupogen

AN

EMP

C2912 C2913

C2914 C2915

C2916 C2917

C2918 C2919

C2920 C2921

C2922 C2923

C2924 C2925

C2926 C2927

C2928 C2929

C2930 C3087

C3187 C3357

C3358 C3359

C3360 C3361

C3362 C3363

C3364 C3365

C3366 C3367

C3368 C3369

C3370 C3371

C3372 C3373

C3374 C3375

C3376 C3377

 

20

11

D

 

Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Nivestim)

Injection

Nivestim

HH

EMP

C2912 C2913

C2914 C2915

C2916 C2917

C2918 C2919

C2920 C2921

C2922 C2923

C2924 C2925

C2926 C2927

C2928 C2929

C2930 C3087

C3187 C3357

C3358 C3359

C3360 C3361

C3362 C3363

C3364 C3365

C3366 C3367

C3368 C3369

C3370 C3371

C3372 C3373

C3374 C3375

C3376 C3377

 

20

11

D

 

Injection 480 micrograms in 1.6 mL

Injection

Neupogen

AN

EMP

C2912 C2913

C2914 C2915

C2916 C2917

C2918 C2919

C2920 C2921

C2922 C2923

C2924 C2925

C2926 C2927

C2928 C2929

C2930 C3087

C3187 C3357

C3358 C3359

C3360 C3361

C3362 C3363

C3364 C3365

C3366 C3367

C3368 C3369

C3370 C3371

C3372 C3373

C3374 C3375

C3376 C3377

 

20

11

D

 

Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Neupogen)

Injection

Neupogen

AN

EMP

C2912 C2913

C2914 C2915

C2916 C2917

C2918 C2919

C2920 C2921

C2922 C2923

C2924 C2925

C2926 C2927

C2928 C2929

C2930 C3087

C3187 C3357

C3358 C3359

C3360 C3361

C3362 C3363

C3364 C3365

C3366 C3367

C3368 C3369

C3370 C3371

C3372 C3373

C3374 C3375

C3376 C3377

 

20

11

D

 

Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Nivestim)

Injection

Nivestim

HH

EMP

C2912 C2913

C2914 C2915

C2916 C2917

C2918 C2919

C2920 C2921

C2922 C2923

C2924 C2925

C2926 C2927

C2928 C2929

C2930 C3087

C3187 C3357

C3358 C3359

C3360 C3361

C3362 C3363

C3364 C3365

C3366 C3367

C3368 C3369

C3370 C3371

C3372 C3373

C3374 C3375

C3376 C3377

 

20

11

D

 

 

 

 

 

 

 

[4]            Schedule 1, entry for Infliximab

 

    omit from the column headed Responsible Person:

                    SH

 

                and substitute:

                    JC

 

[5]            Schedule 1, entry for Maraviroc

 

    omit from the column headed Responsible Person (all instances):

                    PF

 

               and substitute (all instances):

                    VI

 

[6]            Schedule 1, entry for Sirolimus

 

    substitute:

 

Sirolimus

Tablet 0.5 mg

Oral

Rapamune

PF

EMP

C1650 C3355

 

200

5

C

 

Tablet 1 mg

Oral

Rapamune

PF

EMP

C1650 C3355

 

200

5

C

 

Tablet 2 mg

Oral

Rapamune

PF

EMP

C1650 C3355

 

200

5

C

 

Oral solution 1 mg per mL, 60 mL

Oral

Rapamune

PF

EMP

C1650 C3355

 

200

5

C

 

 

 

 

[7]          Schedule 2:

                   

                after:

SC

Bayer Australia Ltd

22 000 138 714

 

      omit:

SH

Schering-Plough Pty Limited

57 000 235 245

 

 

[8]          Schedule 2:

                after:

VI

ViiV Healthcare Pty Ltd

46 138 687 448

 

                   omit:

WX

Wyeth Australia Pty Limited

16 000 296 211

 

Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 

See http://www.frli.gov.au.